Zevra Therapeutics (ZVRA) is back in focus after requesting that a new patent for its approved Niemann Pick type C treatment MIPLYFFA be added to the FDA’s Orange Book, with the goal of extending exclusivity through 2041.

The Orange Book patent move has arrived alongside strong momentum, with Zevra’s share price delivering a 63.79% year to date return and a 31.22% 90 day share price return. The 3 year total shareholder return of 134.71% contrasts with a 5 year total shareholder return that is down 8.93%.

If you are looking beyond rare disease stocks, this could be a good moment to use this strength as a reference point and scan 39 healthcare AI stocks

With the stock up sharply this year, trading at a value score of 6 and at a large discount to average analyst targets and intrinsic estimates, is Zevra still undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 47.5% Undervalued

With Zevra trading at $13.66 against a narrative fair value of $26.00, the most widely followed view highlights a large gap between price and potential.

With $217.7 million in nondilutive capital and an SG&A infrastructure that is already at critical mass, Zevra is competitively positioned to accelerate clinical development, pursue new in-licensed assets, and capture additional pipeline growth opportunities without new financing, enabling significant earnings and margin expansion from organic and inorganic growth.

This narrative explains that valuation gap by focusing on revenue expansion, shifting margins, and a future earnings multiple that is below many peers while still implying meaningful upside.

Result: Fair Value of $26.00 (UNDERVALUED)

However, this bullish setup can unravel if rare disease markets saturate faster than expected, or if products like OLPRUVA continue to underperform and trigger further write downs.

Next Steps

The mix of optimism and concern around Zevra is clear, so use that tension as a prompt to move quickly and check the company's full picture for yourself with 5 key rewards and 1 important warning sign

Looking for more investment ideas?

If Zevra has sharpened your focus, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.

• Spot potential value early by scanning screener containing 21 high quality undiscovered gems before they attract wider attention.
• Prioritize resilience by reviewing 63 resilient stocks with low risk scores that may better match your comfort with volatility.
• Target quality at a discount by assessing 46 high quality undervalued stocks that combine fundamentals with appealing pricing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.